DE122007000095I1 - Papillomavirus vakzine - Google Patents

Papillomavirus vakzine

Info

Publication number
DE122007000095I1
DE122007000095I1 DE122007000095C DE122007000095C DE122007000095I1 DE 122007000095 I1 DE122007000095 I1 DE 122007000095I1 DE 122007000095 C DE122007000095 C DE 122007000095C DE 122007000095 C DE122007000095 C DE 122007000095C DE 122007000095 I1 DE122007000095 I1 DE 122007000095I1
Authority
DE
Germany
Prior art keywords
papilloma virus
virus vaccine
antibodies
useful
mimics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE122007000095C
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25416951&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE122007000095(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of DE122007000095I1 publication Critical patent/DE122007000095I1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
DE122007000095C 1992-06-25 1993-06-24 Papillomavirus vakzine Pending DE122007000095I1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90310992A 1992-06-25 1992-06-25
PCT/US1993/006109 WO1994000152A1 (en) 1992-06-25 1993-06-24 Papillomavirus vaccines

Publications (1)

Publication Number Publication Date
DE122007000095I1 true DE122007000095I1 (de) 2008-03-27

Family

ID=25416951

Family Applications (9)

Application Number Title Priority Date Filing Date
DE122007000098C Pending DE122007000098I1 (de) 1992-06-25 1993-06-24 Papillomavirus vakzine
DE69334192T Expired - Lifetime DE69334192T2 (de) 1992-06-25 1993-06-24 Papillomavirus vakzine
DE122007000097C Pending DE122007000097I1 (de) 1992-06-25 1993-06-24 Papillomavirus vakzine
DE122007000094C Pending DE122007000094I1 (de) 1992-06-25 1993-06-24 Papillomavirus vakzine
DE122007000095C Pending DE122007000095I1 (de) 1992-06-25 1993-06-24 Papillomavirus vakzine
DE122007000096C Pending DE122007000096I1 (de) 1992-06-25 1993-06-24 Papillomavirus vakzine
DE122007000101C Pending DE122007000101I1 (de) 1992-06-25 1993-06-24 Papillomavirus vakzine
DE122007000099C Pending DE122007000099I1 (de) 1992-06-25 1993-06-24 Papillomavirus vakzine
DE122007000100C Pending DE122007000100I1 (de) 1992-06-25 1993-06-24 Papillomavirus vakzine

Family Applications Before (4)

Application Number Title Priority Date Filing Date
DE122007000098C Pending DE122007000098I1 (de) 1992-06-25 1993-06-24 Papillomavirus vakzine
DE69334192T Expired - Lifetime DE69334192T2 (de) 1992-06-25 1993-06-24 Papillomavirus vakzine
DE122007000097C Pending DE122007000097I1 (de) 1992-06-25 1993-06-24 Papillomavirus vakzine
DE122007000094C Pending DE122007000094I1 (de) 1992-06-25 1993-06-24 Papillomavirus vakzine

Family Applications After (4)

Application Number Title Priority Date Filing Date
DE122007000096C Pending DE122007000096I1 (de) 1992-06-25 1993-06-24 Papillomavirus vakzine
DE122007000101C Pending DE122007000101I1 (de) 1992-06-25 1993-06-24 Papillomavirus vakzine
DE122007000099C Pending DE122007000099I1 (de) 1992-06-25 1993-06-24 Papillomavirus vakzine
DE122007000100C Pending DE122007000100I1 (de) 1992-06-25 1993-06-24 Papillomavirus vakzine

Country Status (12)

Country Link
US (2) US20020068326A1 (de)
EP (2) EP1835029A1 (de)
AT (1) ATE380871T1 (de)
AU (1) AU697743C (de)
DE (9) DE122007000098I1 (de)
DK (1) DK0647140T3 (de)
ES (1) ES2294778T3 (de)
FR (1) FR07C0073I2 (de)
LU (8) LU91395I2 (de)
NL (8) NL300315I2 (de)
PT (1) PT647140E (de)
WO (1) WO1994000152A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000084I1 (de) 1991-07-19 2008-03-27 Univ Queensland St Lucia Impfstoff gegen Humanes Papillomavirus (Typ 18)
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
DE4415743C2 (de) * 1994-05-04 1996-10-10 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
PT757717E (pt) * 1994-05-16 2006-09-29 Merck & Co Inc Vacinas de papilomavirus
AU683564B2 (en) * 1994-05-17 1997-11-13 University Of Queensland, The Recombinant papilloma virus L1
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
CZ87597A3 (cs) * 1994-09-22 1998-01-14 Merck And Co., Inc. Molekula DNK kódující lidský papilomavirus typu 6A a použití této molekuly
WO1996011272A2 (de) 1994-10-07 1996-04-18 Medigene Gesellschaft Für Molekularbiologische Diagnostik, Theraphie Und Technologie Mbh Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
US5840306A (en) * 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
US5820870A (en) * 1995-03-22 1998-10-13 Merck & Co., Inc. Recombinant human papillomavirus type 18 vaccine
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US6908615B1 (en) 1996-03-18 2005-06-21 Merck & Co., Inc. DNA encoding human papilloma virus type 18
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
WO1999001557A1 (en) * 1997-07-03 1999-01-14 University Of Colorado, University Technology Corporation Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy
US6228368B1 (en) 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
WO2000002924A1 (en) * 1998-07-13 2000-01-20 Loyola University Of Chicago Papillomavirus cellular receptor
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
US7357936B1 (en) * 1998-10-16 2008-04-15 Smithkline Beecham Biologicals, Sa Adjuvant systems and vaccines
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
EP1425423B1 (de) 2001-08-13 2010-06-23 University of Rochester Transkutane immunisierung gegen papillomavirus mit virusähnlichen papillomaviruspartikeln
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
DK1944318T3 (da) 2003-07-21 2011-06-14 Transgene Sa Multifunktionelle cytokiner
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
AU2007354917B2 (en) 2006-09-26 2013-06-06 Access To Advanced Health Institute Vaccine composition containing synthetic adjuvant
LT2137210T (lt) 2007-03-02 2016-12-27 Glaxosmithkline Biologicals Sa Naujas būdas ir kompozicijos
US9623098B2 (en) 2008-05-26 2017-04-18 Cadila Healthcare Limited Combined measles-human papilloma vaccine
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB0820822D0 (en) 2008-11-13 2008-12-24 Inst Catala D Oncologia Novel product and processes
EP2414512A1 (de) * 2009-04-03 2012-02-08 Deutsches Krebsforschungszentrum Verbesserte herstellung papillomavirus-ähnlicher partikel mit einem modifizierten baculovirus-expressionssystem
CA2764374C (en) 2009-06-05 2019-11-19 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
EP3730943A1 (de) 2010-04-08 2020-10-28 University of Pittsburgh - Of the Commonwealth System of Higher Education Zellenassay mit b-zellen-antigenen
NZ616304A (en) 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
TR201908003T4 (tr) 2012-02-07 2019-06-21 Infectious Disease Res Inst TLR4 agonistleri içeren gelişmiş adjuvan formülasyonları ve bunların kullanım metotları.
SI2850431T1 (en) 2012-05-16 2018-08-31 Immune Design Corp. Vaccine against HSV-2
JP6430949B2 (ja) 2012-10-23 2018-11-28 エモリー ユニバーシティ Ｇｍ−ｃｓｆとｉｌ−４のコンジュゲート、組成物、ならびにそれに関連する方法
EA032326B1 (ru) 2013-04-18 2019-05-31 Иммьюн Дизайн Корп. Монотерапия gla для применения в лечении рака
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
BR112016015422A2 (pt) 2013-12-31 2017-10-24 Infectious Disease Res Inst formulações de vacina de frasco único
EP3420355A1 (de) 2016-02-22 2019-01-02 Boehringer Ingelheim Vetmedica GmbH Verfahren zur immobilisierung von biomolekülen
BR112018073676B1 (pt) 2016-05-16 2023-10-03 University Of Virginia Patent Foundation Lipossomas peguilados e métodos de uso
EP4112638A1 (de) 2016-05-16 2023-01-04 Access to Advanced Health Institute Formulierung mit tlr-agonist und verfahren zur verwendung
CN109195587A (zh) 2016-06-01 2019-01-11 传染病研究所 含上胶剂的纳米明矾颗粒
US11141377B2 (en) 2017-06-15 2021-10-12 Infectious Disease Research Institute Nanostructured lipid carriers and stable emulsions and uses thereof
US20200276299A1 (en) 2017-09-08 2020-09-03 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
WO2020243115A1 (en) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
US20230310323A1 (en) 2020-09-04 2023-10-05 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106626A (en) * 1980-12-22 1982-07-02 Teijin Ltd Cytotoxic protein complex and its preparation
US4455296A (en) * 1982-02-02 1984-06-19 Board Of Regents, The University Of Texas System Hybrid cell lines producing monoclonal antibodies directed against Haemophilus influenzae
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
FR2524487B1 (fr) * 1982-04-05 1985-11-22 Pasteur Institut Fragments d'adn codant pour des polypeptides contenant au moins un determinant antigenique des papillomavirus, notamment du type hpv 1a et polypeptides correspondants
US4596674A (en) * 1984-09-11 1986-06-24 Merck & Co., Inc. Immunogenic HAV peptides
DE3625257A1 (de) * 1986-07-23 1988-02-04 Behringwerke Ag Expressionsprodukte der menschlichen papillomviren typ 16 und 18, fuer diese proteine spezifische antikoerper und diese antikoerper bzw. entsprechende dna enthaltende diagnostika
NZ223009A (en) * 1986-12-31 1990-06-26 Nl Rivm Of Thoven Oligosaccharides containing d-ribose d-ribitol and phosphate units mimicing haemophilus influenzae type b antigens
EP0320942A3 (de) * 1987-12-18 1989-10-04 American Cyanamid Company Polysaccharide und makromolekulare Verbindungen davon
KR910016343A (ko) * 1990-03-20 1991-11-05 스타인, 부그 사람 파필로마바이러스(hpv) 16 단백질의 혈청반응성 에피토프
DE122007000084I1 (de) 1991-07-19 2008-03-27 Univ Queensland St Lucia Impfstoff gegen Humanes Papillomavirus (Typ 18)

Also Published As

Publication number Publication date
AU1135295A (en) 1996-02-08
DK0647140T3 (da) 2008-02-04
NL300319I1 (nl) 2008-03-03
DE122007000100I1 (de) 2008-03-27
DE69334192T2 (de) 2008-12-04
FR07C0073I1 (de) 2008-01-02
EP0647140B1 (de) 2007-12-12
LU91396I2 (fr) 2008-02-14
US8012679B1 (en) 2011-09-06
NL300317I1 (nl) 2008-02-01
LU91394I2 (fr) 2008-02-14
DE122007000094I1 (de) 2008-03-27
WO1994000152A1 (en) 1994-01-06
NL300322I1 (nl) 2008-03-03
NL300318I2 (nl) 2008-03-03
NL300318I1 (nl) 2008-02-01
PT647140E (pt) 2007-12-27
DE122007000097I1 (de) 2008-03-27
ES2294778T3 (es) 2008-04-01
LU91393I2 (fr) 2008-02-14
FR07C0073I2 (fr) 2012-08-03
NL300321I1 (nl) 2008-03-03
AU697743B2 (en) 1998-10-15
EP0647140A1 (de) 1995-04-12
DE122007000099I1 (de) 2008-03-27
LU91397I2 (fr) 2008-02-14
AU697743C (en) 2007-06-14
DE122007000101I1 (de) 2008-03-27
LU91395I2 (fr) 2008-02-14
US20020068326A1 (en) 2002-06-06
NL300315I1 (nl) 2008-02-01
EP1835029A1 (de) 2007-09-19
LU91400I2 (fr) 2008-02-14
DE122007000098I1 (de) 2008-03-27
DE69334192D1 (de) 2008-01-24
LU91398I2 (fr) 2008-02-14
NL300316I1 (nl) 2008-02-01
NL300320I1 (nl) 2008-03-03
ATE380871T1 (de) 2007-12-15
LU91399I2 (fr) 2008-02-14
NL300315I2 (nl) 2008-03-03
DE122007000096I1 (de) 2008-03-27
EP0647140A4 (de) 1997-03-19

Similar Documents

Publication Publication Date Title
DE69334192D1 (de) Papillomavirus vakzine
DE122008000010I1 (de) Sich selbst-zusammenbauende rekombinante hpv16 papillomavirus-hüllproteine
Schlegel et al. Protecting against canine oral papillomavirus